Drug Profile
YYB 101
Alternative Names: CLM-101; NOV 1105; YYB101Latest Information Update: 08 Dec 2023
Price :
$50
*
At a glance
- Originator Yooyoung Pharmaceutical
- Developer National OncoVenture; Yooyoung Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Hepatocyte growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- No development reported Solid tumours
Most Recent Events
- 20 Oct 2023 Efficacy and adverse events data from a phase I/II trial in Colorectal cancer presented at the 48th European Society for Medical Oncology Congress 2023 (ESMO 2023)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in South Korea (IV, Infusion)
- 21 Dec 2021 CellabMED in collaboration with Yooyoung Pharmaceutical completes a phase II clinical trials in Colorectal cancer (Adjuvant therapy, Metastatic disease, Late-stage disease, Recurrent, Second-line therapy or greater) in South Korea (IV) (NCT04368507)